Side-by-side · Research reference

GHRP-6vsKPV

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1Reviewed10/36 cited

BAnimal-StrongDraft13/39 cited

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

01Mechanism of Action

Parameter

GHRP-6

KPV

Primary target

Ghrelin receptor (GHS-R1a)Bowers 1990

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Downstream effect

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Feedback intact?

—

No melanocortin receptor binding

Origin

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Antibody development

—

02Dosage Protocols

Parameter

GHRP-6

KPV

Standard dose

100–200 mcg per injectionBowers 1990

200–500 mcg / day SQ or oralDalle-Pang 2024

Frequency

1–3× per day

Daily or 2–3× per week

Lower / starter dose

50 mcg per dose

100 mcg / day

Evidence basis

Phase 1 + clinical practiceBowers 1990

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Duration

8–12 weeks on / 4 off

4–8 weeks per cycle

Reconstitution

Bacteriostatic water

Bacteriostatic water (SQ form)

Timing

Pre-meal preferred for appetite support

No specific time; often taken with / before meals (oral)

Half-life

~15 minMalagón 1999

Hours (estimated; rapid tissue uptake)

04Side Effects & Safety

Parameter

GHRP-6

KPV

Hunger

Pronounced — defining feature vs ipamorelin

—

Cortisol elevation

Mild

—

Prolactin elevation

Mild

—

Injection site reaction

Mild

Mild irritation

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

Avoid — insufficient data

GI symptoms

—

Rare nausea (oral form)

Pigmentation

—

None (unlike full α-MSH)Dalle-Pang 2024

Long-term safety

—

Limited human data

Absolute Contraindications

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

KPV

·Pregnancy / breastfeeding

Relative Contraindications

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

KPV

·Active autoimmune disease (theoretical)

05Administration Protocol

Parameter

GHRP-6

KPV

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Add 1 mL bacteriostatic water to vial per labelling.

2. Injection site

SQ — abdomen. Rotate sites.

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

3. Timing

Pre-meal for appetite support; pre-sleep for GH alignment.

Morning preferred; oral form taken with / before meals.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

29–31G, 4–8 mm insulin syringe.

29–31G insulin syringe (SQ form).

06Stack Synergy

GHRP-6

— no documented stacks

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018